A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC east-west study group

Annals of Surgery

Volumn 257, Issue 5, 2013, Pages 929-937

  Torzilli, Guido ^a   Belghiti, Jacques ^b   Kokudo, Norihiro ^c   Takayama, Tadatoshi ^d   Capussotti, Lorenzo ^e   Nuzzo, Gennaro ^f   Vauthey, Jean Nicolas ^g   Choti, Michael A ^h   De Santibanes, Eduardo ⁱ   Donadon, Matteo ^a   Morenghi, Emanuela ^j   Makuuchi, Masatoshi ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b BEAUJON HOSPITAL   (France)

^c UNIVERSITY OF TOKYO   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e MAURIZIANO HOSPITAL   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

Barcelona Clinic Liver Cancer classification; chronic hepatitis; hepatocellular carcinoma; liver cirrhosis; liver surgery; sorafenib

Indexed keywords

BILIRUBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CHILD; DISEASE FREE SURVIVAL; ESOPHAGUS VARICES; EUROPE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY HEALTH CARE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHILD; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876287771     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828329b8     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globo-can 2000. Int J Cancer. 2001;94:153-156.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gas-troenterol. 2002;35:S72-S78.
3. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
5. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
6. Marrero JA. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol. 2006;44:630-632.
7. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723-731.
8. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716.
9. Sala M, Forner A, Varela M, et al. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis. 2005;25:171-180.
10. Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:101-118.
11. Pascual S, Zapater P, Such J, et al. Comparison of staging systems to predict survival in hepatocellular carcinoma. Liver Int. 2006;26:673-679.
12. Wang JH, Changchien CS, Hu TH, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients. Eur J Cancer. 2008;44:1000-1006.
13. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-616.
14. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatec-tomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001;233:379-384.
15. Ng KK, Vauthey JN, Pawlik TM, et al. Is hepatic resection for large or multin-odular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol. 2005;12:364-373.
16. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005;140:450-457.
17. Chirica M, Scatton O, Massault PP, et al. Treatment of stage IVA hepato-cellular carcinoma. Should we reappraise the role of surgery? Arch Surg. 2008;143:538-543.
18. Torzilli G, Donadon M, Marconi M, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg. 2008;143:1082-1090.
19. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908-1916.
20. Capussotti L, Ferrero A, Viganò L, et al. Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol. 2009;35:11-15.
21. Vauthey JN, Dixon E, Abdalla EK, et al. Pretreatment assessment of hepatocel-lular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:289-299.
22. Terminology Committee of the IHPBA. Terminology of liver anatomy and resections. HPB Surg. 2000;2:333-339.
23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
24. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
25. Torzilli G, Montorsi M, Donadon M, et al. "Radical but conservative" is the main goal for ultrasonography-guided liver resection: prospective validation of this approach. J Am Coll Surg. 2005;201:517-528.
26. Torzilli G, Donadon M, Marconi M, et al. Systematic extended right posterior sectionectomy: a safe and effective alternative to right hepatectomy. Ann Surg. 2008;247:603-611.
27. Torzilli G, Palmisano A, Procopio F, et al. A new systematic small for size resection for liver tumors invading the middle hepatic vein at its caval confluence: mini-mesohepatectomy. Ann Surg. 2010;251:33-39.
28. Oken MM, Creech RH, Tormey DC, et al. Toxicity acute response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655
29. Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. Jpn J Surg. 1980;10: 84-87.
30. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
31. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg. 2001;136:528-535.
32. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
33. Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138:1198-1206.
34. Torzilli G, Makuuchi M, Inoue K, et al. No-mortality liver resection for hepa-tocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg. 1999;134:984-992.
35. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322-330.
36. Schroeder RA, Marroquin CE, Bute BP, et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006;243:373-379.
37. Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111:1018-1022.
38. Capussotti L, Ferrero A, Vigano L, et al. Portal hypertension: contraindication to liver surgery? World J Surg. 2006;30:992-999.
39. Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250:922-928.
40. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma. Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.
41. Livraghi T, Brambilla G, Carnaghi C, et al. Is it time to reconsider the BCLC/AASLD therapeutic flow-chart? J Surg Oncol. 2010;102:868-876.
42. Cammà C, Schepis F, Orlando A, et al. Transarterial chemo-embolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47-54.
43. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisa-tion versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
44. Cammà C, Di Marco V, Cabibbo G, et al. Survival of patients with hepato-cellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008;28:62-75.
45. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis, part II: accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503-1510.